Trading Signals: FOLD Stock Price Prediction and Forecast (Thu. May. 31, 2007 - Fri. Dec. 22, 2023)(Amicus Therapeutics Inc)
| FOLD latest price $9.1200 (-3.49%) ($9.0800 - $9.5500) on Mon. Sep. 23, 2019. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 2.52% (three month average) | RSI | 47 | Latest Price | $9.1200(-3.49%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | FOLD declines -1.5% a day on average for past five trading days. | Weekly Trend | FOLD advances 0.3% a week on average for past two weeks. | Market Behavior | Normal for large cap. Normal for small cap. | Correlated ETFs | Broad market will support FOLD advance at 0% a week (0% probability) IBB(60%) XBI(56%) IWO(55%) IWM(52%) IWC(50%) | Factors Impacting FOLD price | FOLD will decline at least -1.26% in a week (0% probabilities). VIXM(-33%) VXX(-19%) TLT(-14%) TIP(-1%) UNG(0%) | | | | | Relative Volatility | | | | Market Trend Strength | -1.26% (StdDev 2.52%) | Hourly BBV | 0 () | Intraday Trend | -3.4% | | | |
|
Resistance Level | $9.67 | 5 Day Moving Average | $9.51(-4.1%) | 10 Day Moving Average | $9.67(-5.69%) | 20 Day Moving Average | $9.67(-5.69%) | To recent high | -31.2% | To recent low | 0% | Market Cap | $2.355b | | | | Amicus Therapeutics, Inc. is a biotechnology company focused on discovering, developing, and delivering medicines for people living with rare metabolic diseases. The company is committed to advancing and expanding a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. Amicus Therapeutics has a portfolio of product opportunities including the first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants; a novel, clinical-stage, treatment paradigm for Pompe disease; and a rare disease gene therapy portfolio. The company was founded on February 4, 2002 and is headquartered in Cranbury, NJ. |